Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution SYDNEY, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high ...

TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) announces that it has acquired 4,038,647 common shares (“Shares”) of Azimut Exploration Inc. (“Azimut”) pursuant to a non-brokered private placement, at a price of C$0.60 per Share for total consideration of C$2,423,188.20 (the “Transaction”). Prior to the Transaction, Centerra beneficially owned, or exercised control or direction over 9,935,000 Shares, representing approximately 9.84% of the i ...

核心观点 UroGen Pharma与IntraGel Therapeutics达成战略期权与研究许可协议及股权投资协议，获得IntraGel的SRGel平台技术及TumoCure候选疗法的独家开发与商业化选择权，旨在扩展肿瘤管线和技术能力 [1][2][3] 协议结构 - 协议包含两个战略组成部分：UroGen获得IntraGel的SRGel平台研究许可及最多三种额外肿瘤产品的独家全球开发与商业化选择权 [2] - UroGen获得独家选择权，可在IntraGel完成二期临床研究后，获得TumoCure（用于晚期头颈癌的在研疗法）的独家全球开发与商业化许可 [2] - UroGen将向IntraGel投资高达700万美元的股权证券 [3] SRGel平台技术 - SRGel是一种可生物降解的储库技术，旨在实现治疗药物在局部区域的持续释放 [4] - 该平台基于专有的无水无溶剂脂肪酸基聚合物基质，单次给药后即可实现可控且延长的药物释放 [7] - 瘤内注射时，可维持高局部药物浓度，同时最小化全身暴露及相关毒性 [9] - 平台灵活性支持多种治疗模式，包括小分子、肽类和生物制剂 [9] - 潜在应用领域涵盖多种实体瘤、体重管理及炎症性疾病 [9] TumoCure候选疗法 - TumoCure是IntraGel的主要候选产品，也是SRGel平台的首次临床应用 [10] - 该疗法将顺铂整合入SRGel可生物降解基质中，通过单次瘤内注射给药 [10] - 设计目标是在数月内于肿瘤组织内提供持续的顺铂释放，同时限制全身暴露 [10] - 已准备好进入二期临床，目前针对不适合全身顺铂放化疗的局部晚期不可手术头颈癌患者 [11] - IntraGel正通过FDA的505(b)(2)监管路径推进开发 [11] - 未来可能适用于肺癌、脑癌、胃肠癌、卵巢癌和睾丸癌等其他实体瘤 [11] 临床数据 - 2026年ASCO年会上公布的早期临床数据显示，TumoCure在1b期患者（N=8）中总体耐受性良好 [6] - 显示出低全身顺铂暴露水平 [6] - 在重度预处理患者群体（包括顺铂治疗耐药患者）中提供了早期抗肿瘤活性迹象 [6] - 研究者报告部分患者的肿瘤相关症状有所改善 [6] 战略意义 - UroGen总裁兼CEO Liz Barrett表示，该协议是扩展UroGen肿瘤管线和技术能力的重要一步 [3] - SRGel技术可补充UroGen在局部药物递送方面的专长，为未来创新创造重要选择性 [3] - IntraGel CEO Peter Siman博士认为，UroGen在局部肿瘤治疗领域的领导地位和商业化阶段经验使其成为推进SRGel平台和加速TumoCure开发的理想合作伙伴 [5] 公司背景 - UroGen是一家专注于泌尿上皮癌和特殊癌症创新疗法开发与商业化的生物技术公司 [1][12] - UroGen拥有RTGel反向热凝胶专有平台技术，旨在改善现有药物的治疗特性 [12] - 首个产品获批用于治疗低级别上尿路尿路上皮癌，第二个产品获批用于复发性低级别非肌层浸润性膀胱癌成人患者 [12]

*8.84 G/T AUEQ (7.02 G/T AU, 21.63 G/T AG, 1.03% CU) OVER 4.8 MMONTREAL, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Troilus Mining Corp. (“Troilus” or the “Company”) (TSX: TLG; OTCQX: CHXMF; FSE: CM5) is pleased to announce results from five drill holes totaling 2,915 metres completed as part of the ongoing Z87 extension drilling program at its gold-copper Troilus Project located in north-central Quebec, Canada. All five holes were extensions of existing drillholes originating from the J Zone and were designed to te ...

Drill hole SNR26-117 returned 10.04m grading 12.18 g/t Au and 103 g/t Ag, extending high-grade gold and silver mineralization below the deepest mining stopes proposed in Westhaven’s 2025 preliminary economic assessment (“PEA”). Drill hole SNR26-110 returned 37.34m grading 6.24 g/t Au and 55 g/t Ag, confirming thick, high-grade gold and silver mineralization at the southeastern margin of the deposit.35,000m resource infill drilling program is >76% complete, with four active drills on the South Zone deposit V ...

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetrationBased on PK data the therapeutic dose is expected to be ≤10mg once dailyTo rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with in ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce a non-brokered private placement of equity for gross proceeds of CAD $500,000 (the “Equity Unit”) and a non-brokered private placement of convertible debentures for gross proceeds of CAD $300,000 from th ...

核心观点 - Electra与Glencore延长钴原料供应协议至2031年，锁定100%原料需求，为2027年加拿大钴精炼厂投产提供保障，并建立从上游钴供应到北美电池级硫酸钴的完整商业路径 [1][2][5] 协议关键条款 - 协议延长至2031年12月31日，覆盖精炼厂2027年投产及产能爬坡所需的100%原料 [1][2] - 五年内供应约10,000公吨含钴量，按当前市价价值超过5亿美元 [8] - Glencore成为长期主要原料供应商，Electra在初始爬坡期后可灵活补充其他钴氢氧化物来源以维持原料多元化 [2][6] 下游需求锁定 - 2026年3月与LG Energy Solution签署更新版约束性条款清单，锁定精炼厂约60%的硫酸钴产量至2029年，并可选延至2032年 [7] - 剩余产能为Electra开发北美电动车、储能及关键矿产市场新客户提供灵活性 [7] 精炼厂项目进展 - 精炼厂位于安大略省，为已获完全许可的棕地项目，目标2027年实现机械竣工 [1][9] - 初始设计年产5,120吨含钴量，结晶器额定产能可达6,500吨/年 [9] - 建成后将成为北美唯一硫酸钴精炼厂，填补区域关键矿产供应链加工能力缺口 [3][9] 公司战略定位 - Electra聚焦建设北美关键矿产供应链，核心项目为北美唯一硫酸钴精炼厂 [10] - 公司还持有爱达荷州钴矿带土地包（含Iron Creek项目），并推进黑粉回收及镍精炼等下游材料机会 [10][11]